GW 842166

Drug Profile

GW 842166

Alternative Names: 842166; 842166X; GW 842166X; Non-cannabinoid CB2 receptor agonist - GlaxoSmithKline

Latest Information Update: 31 Aug 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Anti-inflammatories; Non-opioid analgesics; Pyrans; Pyrimidines; Small molecules
  • Mechanism of Action Cannabinoid receptor CB2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Dental pain; Musculoskeletal pain

Most Recent Events

  • 22 Apr 2005 Data presented at the at the 229th American Chemical Society National Meeting (229th-ACS-2005) have been added to the pharmacokinetics and Pain pharmacodynamics sections
  • 09 Dec 2004 Phase-I clinical trials in Pain in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top